Fenokodin Tablet

Fenokodin Tablet is a pharmaceutical preparation containing a combination of two opioid derivatives designed primarily for antitussive (cough-suppressing) and analgesic (pain-relieving) effects. This medication, manufactured in Turkey, combines 20 mg of Codeine with 10 mg of Dionin (Ethylmorphine) per tablet, providing a dual-action approach to managing persistent cough associated with respiratory conditions.

As an opioid-containing medication, Fenokodin is classified under controlled substances and requires appropriate medical supervision for safe and effective use. This review explores the comprehensive profile of Fenokodin, including its composition, pharmacological properties, clinical applications, and important considerations for healthcare providers and patients alike.

Composition and Formulation

Active Ingredients

Fenokodin Tablet contains two primary active pharmaceutical ingredients that work synergistically to provide therapeutic effects. The first component is Codeine (20 mg), a well-established opioid analgesic and antitussive agent derived from opium alkaloids. The second active ingredient is Dionin, also known as Ethylmorphine (10 mg), which is a semi-synthetic opioid derivative with properties similar to codeine but positioned between codeine and morphine in terms of potency.

Excipients

The tablet formulation includes several pharmaceutical excipients that facilitate proper drug delivery and stability. These include lactose (50 mg, derived from cow’s milk), corn starch, povidone, microcrystalline cellulose PH 102, aerosil 200, talc, and magnesium stearate. The tablets are manufactured as white, round tablets with a score line on one side, allowing for potential dose division if prescribed.

Pharmacological Properties

Mechanism of Action

Fenokodin’s therapeutic effects stem from the pharmacological actions of both active ingredients on the central nervous system. Codeine and Ethylmorphine primarily exert their effects through binding to μ-opioid receptors distributed throughout the central nervous system, particularly in the brain stem’s respiratory centers and the cough center in the medulla. This receptor binding initiates a cascade of intracellular signaling that results in decreased cAMP and calcium levels, ultimately hyperpolarizing nociceptive neurons and impairing pain signal transmission. The antitussive effect occurs through direct suppression of the cough reflex at the medullary level, effectively raising the threshold for coughing without necessarily addressing the underlying cause.

Pharmacokinetics

Following oral administration, both active components are absorbed from the gastrointestinal tract. Codeine reaches peak plasma concentration approximately 60 minutes after ingestion, with food having minimal impact on its absorption profile. The apparent volume of distribution for codeine is approximately 3-6 L/kg, indicating extensive tissue distribution.

Both codeine and ethylmorphine undergo extensive hepatic metabolism. Approximately 70-80% of codeine is metabolized by glucuronidation to codeine-6-glucuronide, while about 5-10% undergoes O-demethylation to morphine via the CYP2D6 enzyme system. Similarly, ethylmorphine is also metabolized by CYP2D6 to morphine. This metabolic pathway is clinically significant, as genetic variations in CYP2D6 activity can substantially alter the therapeutic and adverse effect profiles of these medications. The plasma half-life is approximately 3-4 hours, with steady-state concentrations typically achieved within 48 hours of regular dosing.

Therapeutic Indications

Fenokodin Tablet is primarily indicated for the symptomatic treatment of nonproductive, bothersome cough associated with cold and lung infections. The medication particularly targets cough suppression in conditions where coughing does not serve a productive purpose and may disrupt rest or daily activities. While the primary indication is for antitussive effects, the analgesic properties of both active ingredients may provide additional benefit for patients experiencing pain associated with respiratory infections.

It is important to note that Fenokodin is intended for short-term symptomatic relief rather than as a primary treatment for underlying respiratory conditions. Treatment duration should be limited to the shortest period necessary to control symptoms, with consideration for transitioning to non-opioid therapies if extended treatment is required.

Dosage and Administration

Standard Dosing Recommendations

For adult patients, the typical recommended dosage of Fenokodin is one tablet administered 3 to 4 times daily, with approximately 6 hours between doses. The treatment duration should be determined by a healthcare provider based on the patient’s response and clinical condition, but generally limited to the shortest period necessary to control symptoms.

For adolescents between 12 and 18 years of age, the maximum daily dose should not exceed 240 mg of total opioid content, divided into four doses with at least 6 hours between administrations. The lowest effective dose should be utilized for the shortest duration possible. If pain relief is not achieved, treatment should be limited to 3 days and reevaluated by a healthcare provider.

Administration Guidelines

Fenokodin tablets should be taken orally, preferably after meals with an adequate amount of water to minimize gastrointestinal irritation. Patients should not crush or chew the tablets as this may alter the drug release profile and increase the risk of adverse effects. The medication should be stored at room temperature, protected from light and moisture, and kept out of reach of children due to its potential for serious harm if accidentally ingested.

Clinical Considerations

Contraindications

Fenokodin is contraindicated in several clinical scenarios where opioid administration poses significant risks. These include hypersensitivity to codeine, ethylmorphine, or any component of the formulation; concurrent use of monoamine oxidase inhibitors (MAOIs) due to risk of serotonin syndrome; pregnancy and breastfeeding due to potential fetal/infant effects; respiratory distress or severe asthma due to risk of respiratory depression; advanced heart conditions including recent myocardial infarction; gallbladder disorders and chronic constipation due to opioid effects on smooth muscle; and children under 12 years of age due to increased sensitivity to respiratory depression.

Special Warnings and Precautions

Healthcare providers should exercise caution when prescribing Fenokodin to patients with compromised respiratory function, as opioids can further depress respiratory drive. Patients with hepatic or renal impairment require dose adjustment due to altered drug metabolism and elimination. There exists potential for abuse and dependence, particularly with prolonged use or in patients with a history of substance use disorders.

The medication may impair cognitive and motor skills, affecting the ability to drive or operate machinery safely. Patients should be advised accordingly. Additionally, abrupt discontinuation after prolonged use may precipitate withdrawal symptoms, necessitating gradual dose tapering.

Drug Interactions

Fenokodin has significant potential for drug interactions that require clinical attention. Concurrent use with other central nervous system depressants, including benzodiazepines, alcohol, and other opioid analgesics, may potentiate respiratory depression, sedation, and hypotension, potentially leading to profound sedation or coma.

Anticholinergic medications may increase the risk of urinary retention and constipation when combined with Fenokodin. CYP2D6 inhibitors may reduce the analgesic efficacy of codeine by preventing its conversion to morphine, while CYP3A4 inducers or inhibitors may alter the metabolism of both active ingredients, affecting their therapeutic and adverse effect profiles.

Adverse Effects

As with other opioid medications, Fenokodin carries risk for various adverse effects. Common side effects include drowsiness, dizziness, sedation, constipation, nausea, and vomiting. These effects are typically dose-dependent and may diminish with continued use.

More serious adverse effects include respiratory depression, particularly in patients with compromised respiratory function or when used concurrently with other CNS depressants. Allergic reactions, though rare, may present as skin rashes, urticaria, or in severe cases, anaphylaxis. Prolonged use may lead to physical dependence, characterized by withdrawal symptoms upon abrupt discontinuation, and psychological dependence or addiction, particularly at higher doses or in susceptible individuals.

Special Populations

Pediatric Use

Fenokodin is contraindicated in children under 12 years of age due to the increased risk of respiratory depression. For adolescents aged 12-18 years, stricter dosing guidelines apply as previously noted, with emphasis on using the lowest effective dose for the shortest duration necessary. Close monitoring is recommended when used in this population.

Geriatric Use

Elderly patients generally do not require specific dose adjustments based solely on age. However, as this population often has decreased renal and hepatic function and increased sensitivity to opioid effects, clinical prudence suggests starting at lower doses with careful titration. Monitoring for respiratory depression, confusion, and constipation is particularly important in geriatric patients.

Renal and Hepatic Impairment

Patients with renal or hepatic impairment require dose reduction due to potentially altered drug metabolism and elimination. In hepatic impairment, the reduced first-pass metabolism may result in higher plasma concentrations of the parent compounds. In renal impairment, accumulation of metabolites may occur, potentially exacerbating adverse effects.

Regulatory Information

Fenokodin is classified as a controlled substance requiring a special prescription in Turkey (Green Prescription), reflecting its opioid content and potential for misuse. As of May 2025, the retail price in Turkey is approximately 96.25 TL, with a product barcode of 8699587011398. The medication is manufactured by Adeka İlaç ve Kimyasal Ürünler San. Ve Tic. A.Ş., a Turkish pharmaceutical company.

Ethylmorphine is classified as a Schedule II controlled substance (as a single entity) and Schedule III (in combination products) in the United States, though Fenokodin specifically is not marketed in the US.

Summery  table